What cautions should be considered when prescribing mirtazapine?

Cautions While Prescribing Mirtazapine

Mirtazapine requires careful monitoring for agranulocytosis/neutropenia, particularly in the first few weeks of treatment, and should be prescribed with extreme caution in elderly patients due to increased risks of somnolence, falls, weight gain, and mortality. 1

Critical Safety Warnings

Agranulocytosis and Bone Marrow Suppression

• Monitor for fever, chills, sore throat, mucous membrane ulceration, or flu-like symptoms 1
• This is a potentially life-threatening adverse effect that can occur even in older adults 2
• Instruct patients to immediately report any signs of infection
• Consider baseline and periodic complete blood counts, especially in the first 4-8 weeks

Serotonin Syndrome Risk

Avoid combining mirtazapine with:

• MAOIs (contraindicated - allow 14-day washout period) 1, 3
• Other serotonergic drugs (SSRIs, SNRIs, TCAs, tramadol, fentanyl, triptans, St. John's Wort, amphetamines) 1, 3
• Even mirtazapine monotherapy can rarely cause severe serotonin syndrome, particularly in frail elderly patients 4

Monitor for: confusion, agitation, tremors, muscle rigidity, hyperreflexia, tachycardia, hypertension, diaphoresis, fever 3

Cardiovascular Concerns

QTc Prolongation and Cardiac Risks:

• Mirtazapine can prolong QTc interval and cause Torsades de Pointes 1
• Use with extreme caution in patients with:
  • Congenital long QT syndrome
  • History of QT prolongation
  • Recent myocardial infarction or significant heart disease 1
  • Concurrent use of other QT-prolonging medications 5

Orthostatic Hypotension:

• Particularly problematic in elderly patients 1
• Use caution in patients with cardiovascular/cerebrovascular disease, dehydration, hypovolemia, or those on antihypertensives 1

Population-Specific Cautions

Elderly Patients (≥65 years)

Mirtazapine poses significantly elevated risks in older adults:

• Increased mortality risk compared to SSRIs (additional 7.8 deaths/1000 person-years) 6, 7
• Higher risk of falls and fractures, particularly in the first 90 days 6
• Greater susceptibility to somnolence, cognitive impairment, and confusion 1
• Start at lower doses (7.5 mg at bedtime) rather than standard 15 mg 8
• More prone to hyponatremia, especially if taking diuretics 1

Renal and Hepatic Impairment

• Reduce dose in patients with hepatic impairment 9
• Consider dose reduction in renal impairment 9
• Monitor transaminases - mirtazapine can cause ALT elevations ≥3x upper limit of normal in 2% of patients 1

Common but Clinically Significant Adverse Effects

Weight Gain and Metabolic Effects

• Appetite increase occurs in 17% of patients (vs 2% placebo) 1
• Weight gain ≥7% of body weight in 7.5% of adults 1
• In pediatric trials, 49% gained ≥7% body weight 1
• Monitor cholesterol (15% develop increases ≥20% above normal) and triglycerides (6% develop levels ≥500 mg/dL) 1

Somnolence

• Occurs in 54% of patients (vs 18% placebo) 1
• Leads to discontinuation in 10.4% of patients 1
• Warn patients about impaired performance: avoid driving and operating machinery until effects are known 1
• Avoid concurrent benzodiazepines and alcohol 1

Hyponatremia

• Can cause SIADH with sodium levels <110 mmol/L 1
• Higher risk in: elderly patients, those on diuretics, volume-depleted patients 1
• Monitor for headache, confusion, weakness, unsteadiness, falls 1
• Notably, mirtazapine has the lowest risk of hyponatremia among antidepressants (1.02% event rate vs 5.59% for SSRIs, 7.44% for SNRIs) 10

Psychiatric Monitoring

Suicidality

• Monitor closely for emergence of suicidal thoughts/behaviors, especially:
  • Early in treatment (first few weeks)
  • During dose adjustments 1
  • In children, adolescents, and young adults

Activation of Mania/Hypomania

• Screen for personal/family history of bipolar disorder before initiating 1
• Symptoms reported in 0.2% of patients 1
• Monitor for agitation, racing thoughts, decreased need for sleep

Seizures

• Use with caution in patients with seizure disorders 1
• Only 1 seizure reported among 2,796 patients in premarketing trials 1

Drug Interactions and Discontinuation

Key Drug Interactions

• Absolute contraindication: MAOIs 1
• Caution with CYP450 interactions (though mirtazapine has fewer than many antidepressants) 8
• Avoid combining with benzodiazepines (risk of oversedation, respiratory depression) 11

Discontinuation Syndrome

• Never abruptly discontinue - taper gradually over 10-14 days 8, 1
• Withdrawal symptoms include: dizziness, sensory disturbances (paresthesias, electric shock sensations), agitation, anxiety, nausea, vomiting, headache 1

Special Clinical Situations

Angle-Closure Glaucoma

• Mirtazapine can cause mild pupillary dilation 1
• Screen susceptible patients and consider prophylactic iridectomy 1

DRESS Syndrome

• Rare but serious: Drug Reaction with Eosinophilia and Systemic Symptoms 1
• Monitor for fever, rash, swollen lymph nodes
• Discontinue immediately if suspected 1

Practical Prescribing Algorithm

Initial Assessment:

1. Screen for bipolar disorder, seizure history, cardiovascular disease, glaucoma risk
2. Obtain baseline CBC, electrolytes, liver function tests
3. Assess fall risk in elderly patients
4. Review all concurrent medications for serotonin syndrome risk

Dosing Strategy:

• Adults: Start 7.5-15 mg at bedtime 8
• Elderly/frail: Start 7.5 mg at bedtime 8
• Maximum: 30 mg at bedtime 8

Monitoring Schedule:

• Weeks 1-4: Weekly assessment for infection symptoms, suicidality, behavioral activation
• Week 4-8: Monitor weight, somnolence, blood pressure (orthostatic)
• Month 3: Repeat CBC, electrolytes, lipid panel, liver function tests
• Ongoing: Monitor for falls, cognitive changes, weight gain